NEWS

February 2, 2022

Supply chain headaches curb ResMed’s ability to meet demand

MELBOURNE: Sleep treatments maker ResMed says there is no way it can keep ... read more

February 2, 2022

Eucalyptus raises $60m eyes off new obesity management drugs

SYDNEY: One of Silicon Valley’s most respected technology investors has led a $60 ... read more

February 2, 2022

Psychedelics trials ramp up despite TGA decision

PERTH: Australian psychedelic drug experiments will continue despite the Therapeutic Goods Administration rejecting ... read more

February 2, 2022

ResMed ready to capitalise on ‘foot fault’ by rival Philips

MELBOURNE: ResMed boss Mick Farrell says the company can secure long-term market share ... read more